Stem, INC

Market Movers (8-K)

See all →
NYSE
Stem, Inc. announced its second quarter 2026 financial results, reporting its fifth consecutive quarter of positive adjusted EBITDA and reaffirming full-year guidance.
NYSE
Stem, Inc. announced the results of its 2026 Annual Meeting of Stockholders, where shareholders voted on director elections, equity incentive plan amendments, executive compensation, and auditor ratification.
NYSE
Stem, Inc. reported Q1 2026 results featuring positive adjusted EBITDA for the fourth consecutive quarter and reaffirmed full-year 2026 guidance.
NYSE
Stem Inc. announced the dismissal of Deloitte & Touche LLP and the engagement of RSM US LLP as its new independent registered public accounting firm.
NYSE
Stem, Inc. has entered into an agreement with Jefferies LLC to establish an at-the-market equity offering program for up to $30 million of its common stock.
Capital raise
NYSE
A U.S. District Court has dismissed with prejudice all claims in the putative securities class action against Stem, Inc. and its former officers.
Better than expected

Quarterly Earnings (10-Q)

See all →
NYSE
Stem, Inc. reported a significantly narrowed net loss for Q3 2025 and a 31% increase in total revenue, driven by strong hardware sales and a strategic shift to software and services.
Better than expected
Delay expected
Capital raise
NYSE
Stem, Inc. reported a significant net income of $202.5 million for Q2 2025, driven by a major debt extinguishment gain and revenue growth, as it pivots to an AI-enabled software and services strategy.
Better than expected
Capital raise
NYSE
Stem Inc. reports increased revenue but continues to operate at a net loss, announcing a significant workforce reduction as part of a strategic shift towards software and services.
Worse than expected
NYSE
Stem Inc. reported a significant decrease in revenue for the third quarter of 2024, alongside a large net loss, as the company transitions to a software and services-focused business model.
Worse than expected
Delay expected
NYSE
Stem Inc. reported a substantial net loss of $582.3 million for the second quarter of 2024, primarily due to a significant decrease in hardware revenue and a large goodwill impairment charge.
Worse than expected
Delay expected
NYSE
Stem Inc. reported a significant decrease in revenue for the first quarter of 2024, alongside a net loss, while making strategic adjustments to its business model.
Worse than expected
Capital raise

Annual Reports (10-K)

NYSE
Stem Inc.'s 2024 10-K filing reveals a company in transition, pivoting towards AI-driven software and services while grappling with significant net losses and a declining stock price.
Delay expected
Worse than expected
NYSE
Stem Inc.'s 10-K filing for the year ended December 31, 2023, outlines the company's financial performance, strategic initiatives, and risk factors.
Delay expected
Worse than expected

Insider Trading (Form 4)

See all →
NYSE
David S Buzby, a Director of Stem, Inc., reported multiple transactions in common stock on August 7, 2026.
NYSE
Krishna Shivram, a Director of Stem, Inc., reported multiple transactions in common stock on August 7, 2026.
NYSE
Adam Daley, a Director of Stem, Inc., reported multiple transactions in common stock on August 7, 2026.
NYSE
Anil Tammineedi, a Director of Stem, Inc., reported multiple transactions in common stock on August 7, 2026.
NYSE
Vasudevan Guruswamy, a Director of Stem, Inc., reported multiple transactions in common stock on August 7, 2026.
NYSE
Laura D Tyson, a Director of Stem, Inc., reported multiple transactions in common stock on August 7, 2026.

Proxy Statements (Def-14A)

See all →
NYSE
Stem, Inc. has filed its 2026 proxy statement, detailing proposals for director elections, an equity incentive plan amendment, and auditor ratification.
NYSE
Stem, Inc. is soliciting shareholder votes for its 2025 Annual Meeting, proposing an increase in its equity incentive plan shares and a reverse stock split, following recent adjustments to executive compensation and a lower-than-expected say-on-pay vote.
Worse than expected
Capital raise
NYSE
Stem Inc. announces a reduction in the proposed share reserve increase under the 2025 Restatement of its Equity Incentive Plan from 7,500,000 shares to 4,000,000 shares.
NYSE
Stem, Inc. has scheduled its 2025 Annual Meeting for June 4, 2025, and is providing proxy materials to stockholders for voting on key proposals.
NYSE
Stem, Inc. announces its 2025 Annual Meeting of Stockholders, featuring proposals for a reverse stock split, an amendment to the equity incentive plan, and director elections.
Worse than expected
NYSE
Stem, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.

Schedule 13G - Passive Investments

NYSE
The Vanguard Group disclosed an amended beneficial ownership of 4.64% in Stem Inc, holding 386,755 shares as of the event date requiring the filing.
NYSE
BlackRock, Inc. has filed an amendment to its Schedule 13G, disclosing a 2.1% passive beneficial ownership stake in STEM, Inc. as of June 30, 2025.